The development of inhibitory antibodies to therapeutic factor VIII (FVIII) in up to 40% of people with severe hemophilia A (HA) is the major complication in treatment/prevention of hemorrhages. The reasons some people with HA develop inhibitors while others do not, remain unclear. In this session from the WFH 2020 Virtual Summit, Sebastien Lacroix-Desmazes, Kathleen […]
Also Available In: Japanese This patient handbook contains basic information about inhibitors, the most serious complication of hemophilia.
Also Available In: English, Spanish This is not an official WFH translation. This resource has been translated with permission by a WFH National Member Organization (NMO), and is shared here with their kind permission. Translating organizations are encouraged to have translations reviewed by local experts, the WFH is not responsible for the translation or for […]